Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)

Exclusion Criteria

• •Clinically significant abnormalities except chronic HBV infection;
• •Any clinically significant liver diseases;
• •Participants with severe infection requiring systemic anti-infection treatment 1 month before enrollment;
• •Active hepatitis C, HIV antibody positive, treponema pallidum antibody positive;
• •Hepatobiliary neoplasm malignant;
• •The laboratory examination results are obviously abnormal;
• •History of vasculitis or signs and symptoms of potential vasculitis;
• •Anti-neutrophil cytoplasmic antibodies (ANCA) was positive at screening.
• •History of extrahepatic disease that may be related to HBV immune status;
• •Administration of immunosuppressants within 3 months prior to screening, except for short-term use (≤2 weeks) or topical/inhaled steroids. Administration of immunomodulators (thymosin) and cytotoxic drugs within 6 months prior to the first study intervention or have a history of vaccination within 1 month prior to screening or planned administration during the study;
• •History of malignancy within the past 5 years or the discovery of suspected tumors during the screening period;
• •Any suspicion of drug component allergy, or allergic constitution (various drug and food allergy, and judged by the investigator to be clinically significant) in participants;
• •Participants who have significant trauma or major surgery within 3 months before screening, or plan to perform surgery during the study;
• •Blood donation or blood loss more than 400 mL within 12 weeks before screening; Blood transfusion; Blood donation or blood loss not less than 200 mL within 1 month before screening;
• •Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;
• •Participants who have received any oligonucleotide or small molecule interfering ribonucleic acid (siRNA) drugs;
• •Any other circumstances or conditions for which the investigator considers that the participants are inappropriate to participate in the study.